Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study Riccardo Bomben 1, Francesca Maria Rossi , Filippo Vit, Tamara Bittolo, Antonella Zucchetto, Robel Papotti, Erika Tissino, Federico Pozzo , Massimo Degan, Jerry Polesel , Pietro Bulian, Roberto Marasca , Gianluigi Reda , Luca Laurenti, Jacopo Olivieri, Annalisa Chiarenza, Roberta Laureana, Massimiliano Postorino, Maria Ilaria Del Principe, Antonio Cuneo, Massimo Gentile, Fortunato Morabito, Gilberto Fronza , Agostino Tafuri, Francesco Zaja, Robin Foà , Francesco Di Raimondo, Giovanni Del Poeta and Valter Gattei 1✉


© The Author(s) 2023
Leukemia (2023) 37:914-918; https://doi.org/10.1038/s41375-023-01845-9 TO THE EDITOR Disruption of the TP53 gene, either by deletion at chromosome 17p13.1 (del17p) or mutations, is the most important prognostic/ predictive biomarker in chronic lymphocytic leukemia (CLL), also in the context of the novel target therapies including ibrutinib [1][2][3][4]. Although TP53 deletion and mutations mostly co-occur and are considered as equal prognosticators, the prognostic value of isolated or concomitant mutations and deletions remains unclear [2,3]. Here we applied an ultra-deep next-generation sequencing (NGS) approach in CLL patients treated with ibrutinib, to investigate the clinical impact of TP53 mutations and del17p, either concomitant or isolated, or in relation to their disruption burden.
This study, generated in the framework of an institutional Italian multicenter working group on CLL ("Campus CLL"), is a retrospective/multicenter analysis of 229 CLL patients treated with ibrutinib in the current clinical practice. All cases have been either referred to a single institution for molecular and cytogenetic analyses (February 2014-February 2021), or retrospectively referred by delivering frozen cell samples taken prior to starting ibrutinib treatment. Clinical outcome data were updated as of October 2021. Eighty patients, included in a previous study [3], are presented here with an updated median follow-up (24.7 months). As a stringent criterion, only patients assayed for TP53 mutation and 17p deletion in the same blood sample taken within 6 months prior to the start of ibrutinib were included. Median follow-up from ibrutinib treatment was 36.3 months (95% CI 29.5-41.5 months); 51 patients were treatment naïve (TN) and, 178 refractory/relapsed (RR). In accordance with the ERIC recommendations for TP53 disruption [5], mutation analyses were always carried out on samples containing >80% tumor cells; when lower than the 80% cutoff, CD19 positive CLL cells were purified by cell sorting. Briefly, analysis of TP53 mutations was performed with an amplicon-based strategy, covering exons 2-11, as previously reported [4]. A minimum coverage of 2,000X was obtained for each sequence in 100% of the analyzed positions, with a limit of detection of 0.3% VAF; TP53 mutated cases with less than 2% VAF were all confirmed by a second independent NGS run starting from DNA [4]. Moreover, selected low-VAF TP53 mutations were verified by a different experimental approach (digital droplet PCR, ddPCR). BTK and PLCG2 mutations related to ibrutinib resistance were studied by NGS. Interphase FISH was performed to detect del17p and 11q22.3 deletion (del11q) [4]. Further methodological details are provided in Supplementary Information. The clinical and biological baseline characteristics of patients [6] are detailed in Supplementry Table S1. All statistical analyses were performed by using standard methods. Overall survival (OS) and progression free survival (PFS) were computed from date of ibrutinib treatment to date of death or progression/ suspension (events), respectively, or last follow-up (censoring). Molecular studies were blinded to the study end points.
The combination of del17p with TP53 mutation data identified 95 cases without any TP53 aberrations (non-del17p/non-TP53mut), 8 del17p only cases, 60 TP53-mutated only cases (28 low-VAF), and 66 cases bearing both del17p deletion and TP53 mutations (7 low-VAF). Only patients with concomitant TP53 mutations and del17p showed significantly shorter OS/PFS intervals compared to non-del17p/non-TP53mut cases, while no difference in OS/PFS was found in patients presenting single aberration (Fig. 1C, D). The simultaneous presence of TP53 mutations and del17p confirmed its detrimental clinical impact by univariable analysis and remained independent predictor for short OS/PFS by multivariable analyses together with the number of previous lines of therapy and anemia; consistently, these variables were the most frequently selected by internal bootstrap validation (Table 1). Given the low number of patients of some subgroups (e.g. 8 del17p alone cases), these results need to be confirmed in larger cohorts.
At variance from chemo-immunotherapy where the presence of a single TP53 mutation, even with a low-VAF, is associated with a worse outcome [4,12], in the ibrutinib setting only cases presenting a more complex disruption of the TP53 function, due to the concomitant presence of mutations and deletions, fail to have the best benefit from therapy. Our results are in keeping with recent findings suggesting that only double-hit aberrations (i.e. more than one TP53 mutation or TP53 mutation and del17p) are independently associated with a shorter outcome in ibrutinib-treated patients, single-hit aberrations (a single TP53 mutation or del17p only) having an outcome comparable to that of TP53wt patients [2]. Differently from Brieghel et al. [2], however, in our cohort, TP53 mutated patients with more than one mutations but without del17p failed to experience a significantly worse prognosis respect to patients without any aberrations (data not shown). In the present series, 52/66 cases concomitantly bearing del17p and TP53 mutations (79%) bore TP53 mutations and/or 17p deletion in most of the neoplastic clone (Supplementry Table S3). We could, therefore, speculate that the genetic instability fostered by such a massive TP53 disruption might eventually lead to the development of more complex genetic lesions, known to correlate with dismal outcomes in the ibrutinib setting [11,13]. Our finding may help to explain previous reports of ibrutinib-treated CLL in which TP53 mutations failed to have a prognostic impact [12], and in which the simultaneous presence of TP53 mutations and deletion was not investigated.
The evolution of TP53 mutated clones was assessed in 38 patients by longitudinal NGS analysis of paired samples collected at pre-treatment (median time, −0.9 month; range −6.0-0.0) and during (non-relapsed cases; n = 22) or after (relapsed cases; n = 16) ibrutinib treatment (median time interval, 31.8 months, range 3.0-76.9). For relapsed cases, the second time point was collected in close proximity of progression (median time, −0.7 months, range −3.0-1.0 months). No significant differences were observed between relapsed and non-relapsed cases in relation to the timing of the second sampling (P = 0.74). Of a total of 127 TP53 mutations, 92 were present before and 106 after treatment; among these, 21 mutations (median VAF, 1.7%, range 0.4-52.3%) disappeared during the course of treatment, while 35 were newly identified (median VAF, 1.0%, range 0.4-95.2%; Supplementry Table S5). Among relapsed cases, 15/16 showed either a prominent expansion (i.e. a VAF increase greater than 20%) or stability (i.e. VAF variations within the range of 20% VAF variation) over time of the TP53 mutated clone(s) (Fig. 1E). Conversely, in the context of non-relapsed patients, 3 cases presented a VAF increase of the TP53 mutated clones, 13 remained stable, and 6 showed a VAF reduction (Fig. 1F). These data support the idea of a general stability of TP53 subclones under ibrutinib [14], although a positive selection of TP53 mutations over time was slightly overrepresented in relapsed cases (P = 0.04, χ 2 test), suggesting the occurrence of other genetic events complementing the clonal advantage due to TP53 disruption [11,14,15]. Considering the 127 TP53 mutations identified across the different time-points, 8 mutations were shared by ≥3 cases (Supplementry Table S5). Among them, G245S and R175H were found expanded (>20% VAF Fig. 1 Clinical impact of TP53 aberrations in ibrutinib-treated CLL. A Kaplan-Meier curves comparing OS probabilities of 155 non-del17p cases (green line), 74 cases with del17p (black line). B Kaplan-Meier curves comparing OS probabilities of 103 TP53wt cases (green line), 91 cases with high-VAF TP53 mutations (TP53mut_highVAF), i.e., ≥10.0% of VAF (black line), and 35 cases with low-VAF TP53 mutations (TP53mut_lowVAF), i.e., <10.0% of VAF (red line). C Kaplan-Meier curves comparing OS probabilities of 95 cases lacking del17p and TP53 mutations (non-del17p/non-TP53mut, green line), 8 cases with del17p only (del17p/non-TP53mut, black line), 60 cases with TP53 mutations only (non-del17p/TP53mut, red line), and 66 cases with concomitant TP53 mutation and del17p (del17p/TP53mut, blue line). D Kaplan-Meier curves comparing PFS probabilities of 95 cases lacking del17p and TP53 mutations (non-del17p/non-TP53mut, green line), 8 cases with del17p only (del17p/non-TP53mut, black line), 60 cases with TP53 mutations only (non-del17p/TP53mut, red line), and 66 cases with a concomitant TP53 mutation and del17p (del17p/TP53mut, blue line). In Kaplan-Meier curves, cases with more than one mutation are classified according to the mutation with the highest VAF (see Supplementry Table S3). The number of patients in each group is reported; P values refer to the logrank test. E Clonal evolution of TP53 mutations in longitudinal samples relapsed under ibrutinib treatment (relapsed cases). Graph reports results for 16 CLL patients (65 TP53 mutations) longitudinally studied at two different time-points, the 1 st (x-axis) collected at ibrutinib start and the 2 nd (y-axis) collected after ibrutinib interruption for relapse; overall, VAF values are referred to 65 TP53 mutations, as measured at the two time-points. F Clonal evolution of TP53 mutations in longitudinal samples during ibrutinib treatment (non-relapsed cases). Graph reports results for 22 CLL patients (62 TP53 mutations) longitudinally studied at two different time-points, the 1 st (x-axis) collected at ibrutinib start and the 2 nd (y-axis) collected during ibrutinib treatment; overall, VAF values are referred to 62 TP53 mutations, as measured at the two timepoints. The red color denotes a mutation with a VAF increase greater than 20%. The green color denotes a mutation with a VAF decrease greater than 20%. The dotted parallel lines denote the 20% interval on either side. increase) in 3/4 and 2/3 cases, respectively (Supplementry Table S5), suggesting their possible role in ibrutinib resistance. BTK and PLCG2 mutations, were retrieved in 3/7 relapsed cases presenting a positive selection for TP53 mutations at the relapse time (Supplementry Table S5). Overall, BTK and PLCG2 mutations were discovered in 9/16 (56%) relapsed cases versus 3/22 (14%) patients under ibrutinib treatment (P = 0.006, χ 2 test; Supplementry Table S5).
In conclusion, here we provided evidence that only the copresence of TP53 deletion and mutations, the latter even with a low-VAF representation, and not the single aberrations have a negative prognostic impact in CLL patients under ibrutinib treatment. In practice, this finding points toward the need of a complete assessment of TP53 aberrations to be performed in all CLL patients prior to start ibrutinib treatment. A lower threshold for reporting TP53 mutations (e.g. VAF < 10%) must be evaluated in prospective clinical trial cohorts before it can be accepted as standard for routine practice. Moreover, low-VAF TP53 mutations should be always confirmed by orthogonal assays (e.g. ddPCR) or by repetition [4].

DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding author upon request.